Company Overview of Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc., a biopharmaceutical company, develops therapies to enhance treatment outcomes by optimizing and improving the administration and tolerability of drug therapies. The company develops ITCA 650, a Phase 3 clinical program for type 2 diabetes that consists of 4 separate clinical trials. Its products include a cylindrical titanium alloy reservoir that is inserted under the skin that allows the water from the extracellular fluid to enter the device at one end by diffusing through a semi-permeable membrane directly into a salt osmotic engine that expands to drive a piston at a controlled rate, and forces the drug formulation to be released in a consistent way through th...
155 Seaport Boulevard
Boston, MA 02210
Founded in 1995
Key Executives for Intarcia Therapeutics, Inc.
Executive Chairman, CEO & President
Chief Financial Officer and Vice President of Finance & Operations
Chief Scientific Officer and Vice President
Chief Legal Officer, Vice President and General Counsel
Compensation as of Fiscal Year 2017.
Intarcia Therapeutics, Inc. Key Developments
Intarcia Therapeutics, Inc. Announces Board Changes
Sep 19 17
Intarcia Therapeutics, Inc. announced the appointment of four new members to its board of directors. Patrick Conway, Jim Rosenthal, Dr. Jay Skyler and the Honorable Bob Kerrey will be joining the board. Each of these industry leaders and experts in their fields are expected to add significant and sustained value for Intarcia as it continues to develop and advance life-changing therapeutic options to address treatment and prevention outcomes in some of the most devastating and costly chronic diseases around the world. They will also provide knowledgeable counsel and guidance as Intarcia continues to build its novel portfolio of treatment options that can be used with its disruptive Medici Drug Delivery System Intarcia's innovative and proprietary technology platform that was designed to enable therapies to be delivered just once or twice per year. Dr. Patrick Conway just recently became the President and CEO of Blue Cross Blue Shield of North Carolina. Prior to this he served as the Chief Medical Officer, Deputy Administrator for Innovation and Quality and Director of the Center for Medicare & Medicaid Innovation for the Centers of Medicare and Medicaid Services. There, he was responsible for overseeing the quality of care, innovation and new payment models for the programs that serve the over 140 million Americans for access to health care services through Medicare, Medicaid, the Children's Health Insurance Program, and the Health Insurance Marketplace. Jim Rosenthal is the Chief Executive Officer of BlueteamGlobal and a Senior Advisor at Morgan Stanley. Until recently, he served as the company's Chief Operating Officer after joining the firm nearly a decade ago, where he managed day-to-day operations. Rosenthal currently serves on the Board of Director of HIS Markit, OnDeck and Hyperloop. Rosenthal has a B.A. degree from Yale University and a J.D. degree from Harvard Law School. Dr. Jay Skyler currently serves as a Professor of Medicine, Pediatrics and Psychology in the Division of Endocrinology Diabetes & Metabolism at the Leonard M. Miller School of Medicine at the University of Miami, where he has also held a number of key leadership roles in the clinical and drug development setting. The Honorable Bob Kerrey: Former Senator Bob Kerrey, who represented Nebraska as a United States Senator from 1989-2001 and as its 35th governor, serves as the managing director at Allen & Company, a small investment banking firm in New York City. He is also the executive chairman of the Minerva Project, a for-profit educational organization that provides technology, infrastructure and support services for the Minerva Schools and Keck Graduate Institute. Previously for 10 years, Kerrey served as the President of The New School, a small private university in New York City, during which the university doubled its endowment and experienced growth in enrollment, faculty, scholarship funding, capital projects, research and international engagement. Since concluding his service as a Senator, he continues to serve on key committees including the 9/11 Commission as well as the Iraq and Afghanistan Veterans Association. Kerrey served three years as a Navy SEAL in the U.S. Navy and is a Medal of Honor recipient.
Intarcia Therapeutics, Inc. Announces the Top-Line Results from FREEDOM-3S
Sep 15 17
Intarcia Therapeutics, Inc. announced top-line results from FREEDOM-3S which assessed the tolerability and optimal dosing regimen of two different ITCA 650 (exenatide in osmotic mini-pump) dosing approaches when switching patients with type 2 diabetes from stable therapy with liraglutide to ITCA 650. The trial demonstrated that patients receiving 1.2 or 1.8 mg of an injectable liraglutide treatment can be switched directly to the full dose six-month ITCA 650 60 mcg/day osmotic mini-pumps. Patients tolerated the switch to ITCA 650 very well. There was also no statistically significant difference in safety or tolerability when switching directly to the full dose six-month 60 mcg/day mini-pumps versus first switching to the initial 20 mcg/day three-month mini-pumps followed by a 60 mcg/day six-month maintenance dose. Glycemic control remained stable over the 26-week treatment period after the switch to ITCA 650. Additionally, when patients switched from stable liraglutide 1.2 mg and 1.8 mg injections, an incremental and statistically significant reduction in weight from baseline was observed at week 26. The majority of patients entering the switch study were being treated with 1.8 mg injections of liraglutide. This switch study was undertaken to evaluate whether patients who were already on an injectable GLP-1 receptor agonist required initiation with the lower starting dose of ITCA 650 before titrating up to the full dose longer duration mini-pumps or if these particular patients already on a stable dose of a GLP-1 receptor agonist could be switched straight to the six-month full dose 60 mcg/day mini-pumps without compromising GI tolerability and/or overall tolerability. The study included 136 patients with type 2 diabetes across 37 U.S. trial sites, who were receiving chronic stable doses of liraglutide and metformin. Patients were randomized to receive the recommended ITCA 650 dosing regimen of 20 mcg/day for 13 weeks followed by 60 mcg/day for 13 weeks or 60 mcg/day of ITCA 650 for 26 weeks. The final dose of liraglutide was taken 48 hours prior to randomization and metformin was continued during the 26-week treatment period. Comparison of the tolerability of the two ITCA 650 dose regimens after switching from stable liraglutide treatment was the primary endpoint. Both treatment regimens were equally well tolerated. The majority of patients did not experience nausea or vomiting; the overall incidence over time being consistent with prior studies of ITCA 650, all mild to moderate in severity, and transient. No serious nausea or vomiting were reported. Discontinuation for nausea (0-1.5%) was very low. Overall safety and tolerability was consistent with prior phase three trials. In addition to these results, this FREEDOM-3S study incorporated an updated placement procedure guide that optimizes sub-dermal placement of the mini-pump that facilitates easy removal. This enhanced featured is the result of Intarcia's continuous commitment to product design and a focus on optimizing the patient and provider experiences with the proprietary Medici Drug Delivery System™. No new safety findings for ITCA 650 were identified.
Intarcia Therapeutics, Inc. Presents at UBS Global Healthcare Conference 2017, May-22-2017 11:30 AM
Mar 25 17
Intarcia Therapeutics, Inc. Presents at UBS Global Healthcare Conference 2017, May-22-2017 11:30 AM. Venue: Grand Hyatt New York, 109 E 42nd St., New York , NY 10017, United States. Speakers: Owen P. Hughes, Chief Business Officer and Head of Corporate Development.
Similar Private Companies By Industry
Recent Private Companies Transactions